pharmaphorum

AUGUST 30, 2022

Neurocrine Biosciences has featured on lists of potential takeover candidates for years, but has now taken the lead on a buyout of UK biotech Diurnal that if consummated will extend its therapeutic focus further into hormonal disorders. billion this year, giving it plenty of financial muscle for business development.

Hormones 105

Hormones Sales Clinical Trials Clinical Trials 105

Pharmaceutical Technology

SEPTEMBER 8, 2022

. • Test method development. The information contained within the download document is intended for pharmacists, pharmaceutical executives, sales managers, manufacturers, business development managers, pharmaceutical sales representatives, and any other individual involved in the pharmaceutical compounding sector.

Marketing 100

Marketing Pharmacy Containment Sales 100

Pharmaceutical Technology

MARCH 10, 2023

Pharmaceutical and biotechnology industries widely use freeze-drying systems to protect vaccines, antibodies, antibiotics such as penicillin, blood plasma, proteins, enzymes, hormones, viruses, and bacteria from heat and minimise their biological activity.

Manufacturing 147

Manufacturing Production Containment Antibody 147

The Pharma Data

AUGUST 3, 2021

Research & Development (R&D) expenses increased 12% primarily due to higher research and early pipeline spend and late-stage development program spend, including our recent business development activities. Acquired IPR&D expenses in 2021 were driven by the Five Prime Therapeutics acquisition.

Sales 52

Sales Production Antibody Development 52

XTalks

AUGUST 2, 2023

They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. These systems are similar but differ primarily in hormone dose and duration of use. billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

OCTOBER 26, 2020

. As monotherapy for the treatment of BRCA 1/2 metastatic castration-resistant prostate cancer (mCRPC) patients who have progressed following a prior therapy that included a new hormonal agent based on the Phase 3 PROfound trial. Business Developments. Merck and Seagen Inc.

Sales 40

Sales Vaccine Vaccination Production 40

The Pharma Data

MAY 4, 2021

Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, which had been reported within the results of the Upjohn Business (4) in the first three quarters of 2020 , is now included within the Hospital therapeutic area for all periods presented. Some amounts in this press release may not add due to rounding.

Vaccine 40

Vaccine Vaccination Production Sales 40